tumors may benefit more than HER2+/HR+ tumors from dual HER2 blockade, according to 5-year results from the phase III ALTTO trial. The Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation study, or ALTTO, is an international phase III clinical trial of two targeted. Background: Pre-specified 5-year analyses of the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) Trial.
|Published (Last):||17 February 2011|
|PDF File Size:||12.83 Mb|
|ePub File Size:||15.10 Mb|
|Price:||Free* [*Free Regsitration Required]|
IBCSG 36-07/BIG 2-06 (ALTTO)
Given all of these points, we have doubts about the conclusions of the ALTTO-retrospective findings for obvious reasons: Meta-analysis of individual patient data for 10 women in 17 randomized trials. ALTTO recruited 8, patients between and Oxford University Press is a department of the University of Oxford. Treatment Controversy Eva M. Citing articles via Google Scholar.
ALTTO Trial Finds Dual Anti-HER2 Therapy No Better Than Trastuzumab Alone – The ASCO Post
GlaxoSmithKline GSK was the sponsor and funder of the study until 30 Novafter which these responsibilities were transferred to Novartis. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with trual and distant recurrence after breast-conserving therapy.
Piccart-Gebhart noted in her presentation. The IDMC reported that the comparison of lapatinib alone versus trastuzumab alone crossed the futility boundary, altho that the lapatinib alone arm was unlikely to meet the pre-specified criteria to demonstrate non-inferiority to trastuzumab alone with respect to disease-free survival DFS.
You CAN’T join if Regional nodal irradiation after breast-conserving surgery for early HER2-positive breast cancer: Expert Triap of View: At a median follow-up of 4. The recruitment opened in June and completed in July Sign In or Create an Account. Perez did find something positive in the results, as she noted to the media that the disease-free events that occurred at 4.
Secondary objectives include treatment comparisons with respect to overall survival, time to recurrence, time to distant recurrence, safety and tolerability, incidence of brain metastasis, and analyses conducted separately for cohorts of patients defined by presence or absence of cMyc oncogene amplification, expression level of PTEN and presence or alttto of the p95HER2 receptor.
Jumping higher: is it still possible? The ALTTO trial challenge.
After surgery and a standard treatment with chemotherapy, patients enrolled in ALTTO were randomly assigned to receive one of these four treatments for a period of 1 tria Close mobile search navigation Article navigation. The following dosing schemes were used:. The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab, or their combination in HER2-positive breast cancer.
Patients will be enrolled according to one of two design schemas, with Design 2 trizl two chemotherapy options Design 2 and 2Band will be randomised to one of four treatment regimens within each design schema.
See also Companion Articles Response. J Natl Cancer Inst. Study treatment must start no more than 14 days after randomization For Design 2: Perez reported no potential conflicts of interest. Patients with hormone receptor—positive cancers also received appropriate hormonal therapy. We congratulate Gingras et al. Study treatment must start no more than 14 days after randomization and must be concurrent with taxanes.
Meeting Library | Meeting Library
This is not standard of care and is probably related to different practices in the participating countries. Serious cardiac illness or medical conditions including but not confined to: Receive exclusive offers and updates from Oxford Academic.
Presented December 11, It rtial the largest-ever adjuvant clinical trial in HER2-positive breast cancer, involving 8, women from centers in 44 countries, Dr. It works inside the cells to slow or stop the processes that cause tumour growth and disease progression.
Non-anthracycline platinum containing regimen docetaxel and carboplatin and study treatment must start concomitantly and no more than 14 days after randomisation.
The analysis by hormone receptor status was similar. For full disclosures of all the study authors, visit abstracts.
Effect of radiotherapy after breast-conserving surgery on year recurrence and year breast cancer death: Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: Summary Eligibility for people ages 18 years and up full criteria Location at San Francisco, California and other locations Dates study started May A protocol-specified updated efficacy analysis is planned in 2 years.
These patients have a higher risk of relapse than patients with luminal lesions in both the pretrastuzumab 56 and trastuzumab eras 7.
Unresolved or unstable serious adverse events from prior adjuvant chemotherapy or radiotherapy; Malabsorption syndrome, any disease significantly affecting gastrointestinal function,or resection of the stomach or small bowel, or persons unable to swallow oral medication.
Epub Jan Patients with HER2-positive breast cancer have a greater risk of cancer recurrence due to the aggressiveness of this disease subtype. It also assessed the safety of lapatinib and aims to identify specific molecular markers indicators found in blood or other human tissue to predict which patients will benefit most from lapatinib or trastuzumab.
Therefore, one year of trastuzumab as adjuvant treatment following surgery and chemotherapy with or without radiotherapy for this subtype of breast cancer remains the standard of care.